ZEALAND PHARMA A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 599 DKK | -4.31% |
|
+0.17% | +60.50% |
| Apr. 04 | U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year | DJ |
| Mar. 20 | Zealand Pharma A/S Approves Appointments to the Board | CI |
ETFs positioned on Zealand Pharma A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +1.75% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 1 M€ | -.--% | - | |
| 0.00% | 29 M€ | -2.71% | - | |
| 0.00% | 152 M€ | -3.71% | - | |
| 0.00% | 26 M€ | 0.00% | - |
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
2024-05-16
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
626
DKK
Average target price
782
DKK
Spread / Average Target
+24.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.50% | 5.59B | |
| -2.04% | 104B | |
| +1.70% | 97.42B | |
| +0.79% | 22.2B | |
| -17.62% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.76% | 15.06B | |
| +3.71% | 13.98B | |
| +33.41% | 11.66B |
- Stock Market
- Equities
- ZEAL Stock
- Funds and ETFs Zealand Pharma A/S
